Clinical Trial Update: Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung [Phase 2, Phase 3]

View source ↗

Summary

A National Cancer Institute-sponsored trial is evaluating adding atezolizumab to standard chemotherapy for advanced or metastatic extrapulmonary neuroendocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma | Phase 2, Phase 3 | Status: RECRUITING